Management of severe acute malnutrition in low-income and middle-income countries

Indi Trehan,1,2 Mark J Manary1,3,4

ABSTRACT

Kwashiorkor and marasmus, collectively termed severe acute malnutrition (SAM), account for at least 10% of all deaths among children under 5 years of age worldwide, virtually all of them in low-income and middle-income countries. A number of risk factors, including seasonal food insecurity, environmental enteropathy, poor complementary feeding practices, and chronic and acute infections, contribute to the development of SAM. Careful anthropometry is key to making an accurate diagnosis of SAM and can be performed by village health workers or even laypeople in rural areas. The majority of children can be treated at home with ready-to-use therapeutic food under the community-based management of acute malnutrition model with recovery rates of approximately 90% under optimal conditions. A small percentage of children, often those with HIV, tuberculosis or other comorbidities, will still require inpatient therapy using fortified milk-based foods.

CLINICAL MANIFESTATIONS AND DIAGNOSIS

Severe acute malnutrition (SAM) in children presents in at least three different forms in low-income and middle-income countries (LMICs). Careful, precise anthropometry is essential to accurately diagnose and manage children with SAM. This can be challenging in settings where large numbers of children are being screened in rapid fashion in rural health centres and requires an investment in the training of anthropometrists, provision of reliable and calibrated instruments, and quality control.1 2 Children should have their length measured at least a precision of 0.5 cm, weight to the nearest 100 g or less and mid-upper arm circumference (MUAC) to the nearest 2 mm or less. In practice, length can ideally be measured to the nearest 0.1 cm using rigid height boards, weight can be measured to the nearest 5 g using electronic scales powered by disposable batteries and MUAC to the nearest 1 mm using standard paper insertion tapes. Pitting oedema should be assessed and quantified in the feet, lower legs, hands and face as well.1

Children with acute wasting—mild, moderate or severe (‘marasmus’)—are often weak and emaciated, having suffered a significant amount of weight loss in a relatively brief period prior to presenting for care. Much of the weight loss is initially visible in the groin and axilla, and later in the buttocks, thighs and face. Children with marasmus are often considered to have an ‘old man’ appearance and are often either quite apathetic or inconsolable. Objective, reproducible anthropometric criteria should be used to make the diagnosis of marasmus rather than subjective criteria such as ‘visible severe wasting’.3 Marasmus is diagnosed based on either a MUAC <115 mm or a weight-for-height Z-score (WHZ) more than three SDs below the mean,5 based on the 2006 WHO growth standards.6

When resources are available, it is preferable to assess both MUAC and WHZ to identify children with marasmus as the two populations of children identified by these individual criteria will not overlap uniformly. In most populations, the children identified as severely wasted by WHZ will generally be older and at lower risk of death than those identified by MUAC.7 Colour-coded MUAC tapes requiring no literacy may also be distributed to laypeople to increase screening coverage in rural villages without the need for as many trained health workers. For these reasons, in contexts with limited human or material resources where only one screening method is available, it is preferable to screen by MUAC rather than WHZ.8 While anthropometry alone may classify children as marasmic and prompt therapy, underlying illnesses and triggers such as severe dehydration, malabsorption due to geohelminths, HIV-associated wasting and congenital anomalies should be considered while nutritional rehabilitation is undertaken.

A second form of SAM, kwashiorkor, is diagnosed based upon the cardinal physical finding of symmetric bilateral pitting oedema that begins in the feet (labelled 1+ oedema, figure 1A), progresses to involve the lower legs and hands (2+ oedema, figure 1B) and in severe cases can involve the face (3+ oedema, figure 1C). Kwashiorkor was originally described among children who were rapidly weaned onto low-protein complementary foods from breast milk, and thus the pathophysiology was thought to be primarily one of protein deficiency, but further experience has questioned this hypothesis.9 10 Children with kwashiorkor often have ‘flaky paint’ depigmentation of their skin, commonly leading to frank breakdown, which can serve as a portal of entry for infectious pathogens.11 The acute development of oedema among impoverished children in LMICs, even in children who have previously been growing well, is highly specific for kwashiorkor, although other diagnoses should of course still be kept under consideration, especially among those who do not recover as might be expected.

The third major form of SAM among children in LMICs, marasmic kwashiorkor, presents with both the severe wasting that characterises marasmus and the oedema that characterises kwashiorkor. These children are generally the most ill with the highest risk of mortality.12 The varying routes to these different forms of SAM among children with similar diets, genetics and environments have not been clearly elucidated, but the role of each individual’s...
intestine, as the system will affect the therapies of acute malnutrition and the diagnosis of malnourished children should occur as part of the general medical assessment of all children presenting for care in LMICs. In hospital settings, this should be part of the Emergency Triage Assessment and Treatment system (such as the amount and speed of fluid resuscitation) given for the primary presenting symptom. In outpatient settings, similar assessments for acute malnutrition should occur as part of the Integrated Community Case Management framework.

**Epidemiology and Impact**

More than 500,000 deaths each year among children under 5 years of age are attributable to marasmus, using the WHZ < −3 definition, accounting for >7% of all mortality in this age group. At any given time, some 18 million children in low-income and middle-income countries are estimated to suffer from marasmus, most of them in Asia. However, this is likely a vast underestimate as it does not take into account children aged 6–59 months with MUAC <115 mm, nor has the incidence or prevalence of kwashiorkor been accurately quantified. These estimates also generally do not include acute man-made and natural humanitarian crises, during which large numbers of cases of SAM are also seen. Deservedly, concerted global efforts to address SAM in a cost-effective manner are warranted as reduction of mortality from this disease will contribute markedly to an overall general decrease in child mortality.

The proportion of SAM due to kwashiorkor also varies widely by geography, with very high rates in southern Africa and lower rates in other parts of Africa, Latin America and Asia. Our own experience in West Africa suggests that approximately one-quarter of SAM cases there are due to kwashiorkor while in southern Africa approximately two-thirds to three-fourths of the cases of SAM we treat are due to kwashiorkor. All in all, it seems quite likely that the under-five mortality attributable to SAM exceeds 10%.

What remains incompletely understood and yet of growing importance is the impact of episodes of SAM on a growing child’s risk for metabolic syndrome and obesity in adulthood, particularly given the increasing recognition of a ‘double burden’ of overnutrition in adults superimposed on the endemic crisis of childhood undernutrition in many LMICs.

**Treatment**

After being diagnosed with SAM, each child must be assessed for the presence of clinical complications that would warrant inpatient therapy (figure 2). The essential complication to assess for carefully is anorexia; all children with SAM should thus undergo a supervised test feeding of approximately 30 g of ready-to-use therapeutic food (RUTF). Other common complications include severe dehydration, high fever, respiratory distress, hypoglycaemia with lethargy and evidence of severe anaemia that may require blood transfusion. The clinical assessment for these complications can often—but not always—be streamlined to the appetite test as it is likely that most of these various significant complications will lead to the anaemia that would make a child ineligible for outpatient therapy. Children with SAM, due to chronic medical conditions such as congenital heart disease, cerebral palsy and other syndromes, may not ‘pass’ the appetite test and the therapies described herein for SAM may not be sufficient for them to achieve standard anthropometric goals. Directed therapies for their underlying illnesses should be provided whenever possible and the definition of nutritional recovery should be individualised in these cases as prolonged nutritional supplementation or enrolment in a therapeutic feeding programme may be futile.

Provider-initiated HIV testing and counselling is an important component of the initial management of all children with SAM in high-prevalence areas and can often reveal previously unsuspected cases of HIV in children and their mothers. Children with HIV who are otherwise well-appearing and demonstrate an appetite can still be treated as outpatients, although evidence suggests that early, possibly simultaneous, initiation of antiretroviral therapy in these cases is beneficial.

In areas where active surveillance and case-finding for SAM is being conducted effectively, the vast majority of children with SAM will be identified early in their illness and not have any of these complications and will be able to enter into a feeding programme under the community-based management of acute malnutrition (CMAM) model. This treatment protocol is built upon RUTF as the key element in nutritional rehabilitation. While the most common recipe for RUTF consists of a peanut paste fortified with macronutrients and micronutrients to meet minimum nutrient specifications and quality standards established by the WHO (table 1), novel formulations using locally sourced ingredients are being increasingly studied and developed in a number of settings. Ideally, RUTF will have a very low moisture content in order to minimise the risk of microbial contamination. Children who successfully complete a test feeding
under direct observation by trained staff can generally be discharged home with a 1-week to 2-week supply of RUTF at a dose of approximately 150–200 kcal/kg/day.

Children treated as outpatients should be re-evaluated every 1–2 weeks, or sooner, if complications arise or the child’s condition is worsening. Treatment should continue until they have no more oedema or until WHZ >−2 or until MUAC >125 mm, depending on which enrolment criteria were used. In our experience, most children recover within 10–12 weeks and about half recover within 6 weeks if there are no social or compliance concerns and no acute infections that complicate their care. Caretakers of children who do not improve at each visit should be counselled about proper feeding techniques and be queried about whether any acute infections have developed as these children may need additional medical interventions, sometimes including hospitalisation. Repeating the appetite test and having a low threshold for HIV testing in high-prevalence areas are often helpful.

A number of other additional interventions, such as vitamin A and/or folic acid supplementation, antihelminthic medications such as albendazole or mebendazole, antimalarial medication, measles vaccination and routine antibiotics, are variably included in a number of CMAM regimens. However, among these and despite preliminary concerns that they were not helpful, the routine provision of a short course of oral antibiotics is the only additional intervention to RUTF that has actually been shown to specifically improve recovery rates in this context.

Inpatient therapy consists of a coordinated 10-step protocol (figure 3) whose core element is slow, cautious feeding with F-75 formula every few hours, progressing to F-100 formula as recovery proceeds and when they are able to tolerate this increased solute load. Additional elements of inpatient therapy address hypoglycaemia, hypothermia, dehydration, electrolyte imbalances and micronutrient deficiencies, although

---

Table 1 Nutrient composition of key therapeutic foods used in the treatment of severe acute malnutrition

<table>
<thead>
<tr>
<th></th>
<th>F-75 (100 mL)</th>
<th>F-100 (100 mL)</th>
<th>Ready-to-use therapeutic food (100 g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy (kcal)</td>
<td>75</td>
<td>100</td>
<td>543</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>0.9</td>
<td>2.9</td>
<td>13.6</td>
</tr>
<tr>
<td>Lactose (g)</td>
<td>1.3</td>
<td>4.2</td>
<td></td>
</tr>
<tr>
<td>Potassium (mg)</td>
<td>156</td>
<td>246</td>
<td>1111</td>
</tr>
<tr>
<td>Sodium (mg)</td>
<td>14</td>
<td>44</td>
<td>189</td>
</tr>
<tr>
<td>Magnesium (mg)</td>
<td>10.5</td>
<td>17.7</td>
<td>92</td>
</tr>
<tr>
<td>Zinc (mg)</td>
<td>2</td>
<td>2.3</td>
<td>14</td>
</tr>
<tr>
<td>Copper (mg)</td>
<td>0.25</td>
<td>0.25</td>
<td>1.78</td>
</tr>
<tr>
<td>Osmolarity (mOsm/L)</td>
<td>413</td>
<td>419</td>
<td></td>
</tr>
<tr>
<td>% of total energy from protein</td>
<td>5</td>
<td>12</td>
<td>10–12</td>
</tr>
<tr>
<td>% of total energy from fat</td>
<td>36</td>
<td>53</td>
<td>45–60</td>
</tr>
</tbody>
</table>
these traditional protocols are being reconsidered in many cases.34 Although still an unsettled issue, children with severe dehydration or shock should receive cautious fluid resuscitation as there is at least a strong theoretical risk of fluid overload in these children with compromised cardiac structure and function.34 Children treated as inpatients generally receive empiric antibiotic therapy and arrangements should be made to provide developmentally appropriate sensory stimulation and plan for a phased period of follow-up after initial recovery, which may include supplementary food rations after discharge.

PROGNOSIS
While recovery rates from outpatient therapeutic programmes are generally as good as or better than inpatient programmes,36–38 there have, in fact, not been the most stringent prospective blinded randomised controlled trials that directly test the efficacy of RUTF.39 Nevertheless, more than a decade of operational clinical experience with millions of children has rightly made outpatient management of uncomplicated SAM the de facto standard of care,32 and it is unlikely that such a trial could now ethically be conducted.

In the best circumstances, some 90% of children can be expected to recover from SAM and <5% mortality should be achievable.15 Untreated episodes of severe wasting typically have a mortality rate of 10%–15% per month; while many will recover spontaneously, their cognitive and physical development likely remains stunted. However, the success of current therapies for SAM underestimates overall mortality as those who recover are at continued risk for relapse and death in the long term, especially those who are HIV-infected.40

Further work needs to be done to improve surveillance and case-finding of children with SAM and additional efforts need to be made to treat SAM as a medical emergency, integrating it into the routine delivery of healthcare. This is particularly important in the context of linkage to HIV testing and treatment efforts.27

### Figure 3
Ten-step inpatient management protocol for severe acute malnutrition. Adapted from 2003 WHO guideline.36

<table>
<thead>
<tr>
<th>STEP</th>
<th>STABILIZATION</th>
<th>REHABILITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Treat and prevent HYPOGLYCEMIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Treat and prevent HYPOTHERMIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Treat and prevent DEHYDRATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Correct ELECTROLYTE imbalances</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Treat and prevent INFECTIONS</td>
<td>without iron</td>
<td>with iron</td>
</tr>
<tr>
<td>6. Correct MICRONUTRIENT deficiencies</td>
<td>F-75</td>
<td></td>
</tr>
<tr>
<td>7. Start cautious FEEDING</td>
<td>F-100</td>
<td></td>
</tr>
<tr>
<td>8. Achieve CATCH-UP GROWTH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Provide SENSORY STIMULATION and emotional support</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Prepare for FOLLOW-UP after recovery</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Competing interests None.

Patient consent Obtained.

Provenance and peer review Commissioned; externally peer reviewed.

### REFERENCES


